Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1483 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-30

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)

NCT01376128

Panic Disorder

COMPLETED

Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

NCT01376271

Social Phobia

COMPLETED

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

NCT00658372

Generalized Anxiety Disorder

TERMINATED PHASE3

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

NCT00266747

Anxiety Disorders

COMPLETED PHASE3

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

NCT00031317

Panic Disorder

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Panic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients prescribed PAXIL

Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period

Paroxetine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paroxetine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with depression or in a depressed state
* Patients who start taking paroxetine at 20mg a day

Exclusion Criteria

* Patients who have been treated with paroxetine prior to this investigation
* Patients with hypersensitivity to paroxetine
* Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs
* Concomitant use in patients taking pimozide

Eligible Sex

ALL

Accepts Healthy Volunteers

No